Dupixent (dupilumab) is not off the market. It is an approved medication for several inflammatory conditions.
What conditions does Dupixent treat?
Dupixent is prescribed for the treatment of moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposology, eosinophilic esophagitis, and prurigo nodularis [1].
What is the mechanism of action for Dupixent?
Dupixent works by targeting and blocking two key proteins, IL-4 and IL-13, which are central drivers of inflammation in the conditions it treats [1].
When does Dupixent's patent expire?
Information regarding the patent expiry for Dupixent can be found on DrugPatentWatch.com [2]. Patents for drugs are complex and can involve multiple patents covering different aspects of the drug, such as composition, manufacturing, and method of use. These patents have varying expiry dates.
Can other companies make a version of Dupixent?
The development of generic or biosimilar versions of Dupixent is contingent on the expiry of relevant patents and regulatory approvals. The patent landscape for Dupixent is actively monitored by companies interested in potential market entry for biosimilars. Details about these patents and their status are available through resources like DrugPatentWatch.com [2].
Who makes Dupixent?
Dupixent is developed and marketed by Regeneron Pharmaceuticals, Inc. and Sanofi [1].
What are the potential side effects of Dupixent?
Common side effects reported with Dupixent include injection site reactions, conjunctivitis, oral herpes, and other forms of dermatitis [1].
Is Dupixent available in different forms?
Dupixent is administered as a subcutaneous injection [1].
What clinical trials have been conducted for Dupixent?
Numerous clinical trials have evaluated Dupixent's efficacy and safety across its approved indications. These trials have informed its regulatory approval and are ongoing to explore new uses or patient populations.
How does Dupixent compare to other treatments for its indications?
Dupixent offers a targeted approach to treating inflammatory diseases by inhibiting specific cytokine pathways. Its effectiveness and safety profile are evaluated against existing standard-of-care treatments in clinical practice and studies.
Sources:
[1] https://www.dupixent.com/
[2] https://drugpatentwatch.com/